Research & development increased 187.0%
Research & development changed +187.0% from the comparable as-filed period.
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Research & development changed +187.0% from the comparable as-filed period.
Stock-based compensation changed +445.1% from the comparable as-filed period.
Total assets changed +26.6% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Current assets changed +26.6% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Cash & equivalents changed +20.6% from the comparable as-filed period.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.